Background {#Sec1}
==========

Respiratory tract infections (RTI) are the most common diagnoses in children, especially below the age of 2 years \[[@CR1]\]. They substantially contribute to morbidity and mortality worldwide \[[@CR2]\]. Furthermore, RTI are associated with large societal impacts \[[@CR3]\], including a high health-economic burden \[[@CR4]\], caused by a high hospitalization rate among the very young, causing frequent parental absence from work \[[@CR5]\]. Moreover, antimicrobial consumption is heavily driven by RTI \[[@CR6]\] due to the clinical challenge of distinguishing between viral and bacterial etiologies and the lack of a reliable diagnostic reference standard \[[@CR7], [@CR8]\]. Antimicrobial stewardship (AMS) programs are increasingly implemented \[[@CR9]\] to counteract this antibiotic overuse which is strongly associated with the upsurge in antimicrobial resistance \[[@CR10]\],

The respiratory syncytial virus (RSV) and the Influenza virus (FLU) account for the majority of RTI in infants leading to hospitalization \[[@CR11], [@CR12]\]. With the advent of novel point-of-care tests based on nucleic acid amplification, diagnostic accuracy and turnaround time of results have dramatically increased over the past years, both for RSV and FLU \[[@CR13], [@CR14]\]. Yet, there is only limited data indicating the potential clinical benefit of rapid viral testing as a tool of AMS in the hospital setting \[[@CR15]\]. The overall quality of evidence was generally regarded low, making only for a "weak recommendation" in the latest Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America for implementing an AMS program \[[@CR16]\].

In a recent systematic review with meta-analysis, including both diagnostic accuracy studies and clinical impact studies, no firm conclusion could be made on the clinical impact of viral testing on antibiotic use due to the heterogeneity of the included studies \[[@CR17]\], of which only two had included children.

Little is known about the factors that influence antibiotic prescription in patients with a positive RSV or FLU test. We sought to analyze the rate of antibiotic use in RSV and FLU patients and associated clinical and laboratory factors.

Methods {#Sec2}
=======

Study setting and design {#Sec3}
------------------------

This retrospective, single-center analysis was conducted at the University Children's Hospital Mannheim, Medical Faculty Mannheim of the Heidelberg University, Germany. The local ethics committee approved of the study (2018-832R-MA). All patients below 2 years of age hospitalized for RSV or FLU infection between the April 2014 and April 2018 were included, thereby covering 4 complete epidemic seasons. Patients were identified by a hospital database search for the corresponding ICD-10 codes (J12.1, J21.0, J20.5, B97.4; J09-J11.-) as the primary diagnosis and, to avoid selection bias, also as secondary diagnosis. RSV or FLU infection were each defined as a positive result from a nasopharyngeal swab either in a rapid point-of-care test (Sofia® Influenza A + B Fluorescent Immunoassay and Sofia® RSV Fluorescent Immunoassay; Quidel, San Diego, California, USA) or in a multiplex PCR (Biofire® Filmarray® Respiratory Panel, Biomérieux, Marcy-l'Étoile, France), which comprises adenovirus; coronaviruses 229E, HKU1, OC43, and NL63; human metapneumovirus; human rhinovirus/enterovirus; influenza A (including substrains) and B; parainfluenza viruses 1 to 4; RSV; *Bordetella pertussis*; *Chlamydophila pneumoniae*; and *Mycoplasma pneumoniae*.

Chart review included present and past medical history, family history, preexisting antibiotic therapy, clinical findings, results of laboratory, microbiological and radiological investigations, data on therapy, need for oxygen, intensive care, and length of stay. Clinical appearance was defined as documented as the physical examination upon admission, including "well", "ill", and "septic" appearance. The clinical syndrome was defined according to the discharge diagnosis and/or the documented clinical symptoms on admission, as either upper respiratory tract infection (URTI), bronchitis/bronchiolitis, pneumonia, or fever of unknown origin (FUO).

Case numbers were compared between the seasons to check for imbalances.

We compared children with RSV infection to children with FLU infection. Especially, clinical characteristics and factors contributing to an increased rate of antimicrobial utilization were analysed of RSV and FLU infected children. Furthermore, we defined subgroups of children within each group and compared those treated with antibiotics (RSV+AB+; FLU+AB+) to those who were not treated with antibiotics (RSV+AB-; FLU+AB-), respectively. Antibiotic utilization was defined as any given dose during the hospital stay. We assessed antibiotic therapy in terms of substance and length of therapy.

Statistical analysis {#Sec4}
--------------------

Statistical analyses were performed in SAS (Statistical Analysis System, North Carolina, USA). Mann-Whitney U test was used for group comparison between RSV and FLU. For multiple comparisons, Kruskal-Wallis test and one-way analysis of variance were applied. Logistic regressions were performed to assess potential risk factors for antibiotic utilization.

Results {#Sec5}
=======

Demographic data {#Sec6}
----------------

Overall, 573 children were eligible for analysis, with a median age of 5 months (IQR 2--11) and a male predominance of 325/573 (56.7%). Of the 573 children, 476 were identified as having RSV infection (83.1%), and 95 as having FLU infection (16.6%), while in two patients, RSV-FLU co-infection was detected (0.3%). RSV patients were significantly younger than FLU patients (4 vs. 12 months; *p* \< 0.0001) (Table [1](#Tab1){ref-type="table"}), while 19.5% of RSV patients were 28 days of age or younger and 47.7% 3 months of age or younger. The majority of RSV patients presented during the months January and February (32.4 and 25.4%), while FLU patients were predominantly diagnosed in February and March (43.2 and 25.3%) (Fig. [1](#Fig1){ref-type="fig"}). Table 1Comparison of clincial and laboratory characteristics of RSV and FLU patients; median and interquartile range are indicated for continuous variables; *ns* not significantVariablesRSVFLU*p*-valuesN (%)476 (83.1%)95 (16.6%)Male269/476 (56.5%)55/95 (57.9%)nsAge, months4 (2--8)12 (5.5--18)\< 0.0001Duration of illness, days4 (2--5)3 (2--5)0.0005Fever (≥38.0 °C)330/476 (69.3%)93/95 (97.9%)\< 0.0001Body temperature on admission, °C37.5 (37.1--38.3)38.4 (37.5--39.3)\< 0.0001Peak body temperature, °C38.7 (37.7--39.4)39.9 (39.1--40.1)\< 0.0001Oxygen saturation at admission, %97 (94--98)98 (96--100)0.0002Minimal oxygen saturation, %90 (88--94)96 (90--98)\< 0.0001Need for intensive care16/476 (3.4%)1/95 (1.1%)nsLength of stay, days5 (4--7)4 (3--6.5)0.0023Blood culture obtained165/476 (34.7%)54/95 (56.8%)\< 0.0001CRP on admission, mg/L6.9 (0--17.6)6.6 (0--14.1)nsPeak CRP, mg/L12.3 (5.8--29.2)11.7 (5.4--23.7)nsWBC on admission, 10\^9/L10.7 (8.5--13.2)10.8 (7.1--13.6)nsChest radiography performed135/476 (28.4%)18/95 (18.9%)nsInfiltrate on chest radiogram72/135 (53.3%)13/18 (72.2%)nsPreexisting antibiotic therapy32/476 (6.7%)14/95 (14.7%)0.0188Well appearance32/476 (6.7%)6/95 (6.3%)nsIll appearance245/476 (51.5%)62/95 (65.3%)0.0176Septic appearance168/476 (35.3%)23/95 (24.2%)0.0426Febrile seizure3/476 (0.6%)14/95 (14.7%)\< 0.0001Acute otitis media70/476 (14.7%)33/95 (34.7%)\< 0.0001Upper respiratory tract infection0/476 (0%)47/95 (49.5%)\< 0.0001Bronchitis/Bronchiolitis236/476 (49.6%)6/95 (6.3%)\< 0.0001Pneumonia239/476 (50.2%)21/95 (22.1%)\< 0.0001Fever of unknown origin1/476 (0.2%)21/95 (22.1%)\< 0.0001Death0/4761/95 (1.1%)nsOxygen therapy314/476 (66.0%)23/95 (24.2%)\< 0.0001Length of oxygen therapy, days2 (0--5)0\< 0.0001Antibiotic therapy136/476 (28.6%)21/95 (22.1%)0.2107Fig. 1Distribution of cases for each month for RSV (blue) and FLU (orange)

Seasonality {#Sec7}
-----------

We assessed the seasonal variability (Fig. [1](#Fig1){ref-type="fig"}). Numbers were comparable between the seasons except for one season each with a higher burden of RSV (2016/2017) and FLU (2017/2018).

Baseline risk factors {#Sec8}
---------------------

We assessed patients with respect to a positive past medical history with focus on prematurity, congenital heart disease, congenital diaphragmatic hernia, trisomy 21, and recurrent episodes of bronchitis, but could not find any significant differences, although prematurity and recurrent bronchitis were slightly more common in RSV (4.4 and 4.8%, respectively) than in FLU patients (2.1 and 3.1%, respectively), both missing statistical significance. Furthermore, similar sick contacts were observed for 38.9% of RSV and for 45.3% of FLU patients (statistically not significant).

Clinical presentation, treatment and outcome of RSV and FLU patients {#Sec9}
--------------------------------------------------------------------

Both patient groups presented with similar durations of illness, but a significant number of FLU patients had received antibiotics before presenting to the hospital (14.7% vs. 6.7%; *p* = 0.0188). The clinical syndrome diagnosed upon admission was lower respiratory tract infection (49.6%) or pneumonia (50.2%) for most of the RSV patients (compared to 6.3% und 22.1% for FLU patients, respectively; both *p* \< 0.0001), while in FLU patients, upper respiratory tract infections (49.5%) and FUO (22.1%) accounted for the majority of clinical manifestations (compared to 0.2 and 0% for RSV patients, respectively; both *p* \< 0.0001). In association with this, fever, and also febrile convulsions were significantly more often found in FLU patients (Table [1](#Tab1){ref-type="table"}). Acute otitis media was significantly more often diagnosed among FLU patients (*p* \< 0.0001).

RSV patients needed significantly more often oxygen therapy (66% vs. 24.2%; *p* \< 0.0001) and salbutamol (68.3% vs. 27.1%; *p* \< 0.0001) than FLU patients, and had longer hospital stays (5 vs. 4 days; *p* = 0.0023), while there were no statistically significant differences concerning the need for intensive care and antibiotic therapy. One FLU patient died due to severe pneumonia with suspected bacterial co-infection, leading to respiratory failure.

Laboratory, microbiological and radiological findings in RSV and FLU patients {#Sec10}
-----------------------------------------------------------------------------

No significant differences were found between both groups concerning C-reactive protein (CRP) and white blood cell counts (WBC). Chest radiographs were performed slightly more often in RSV patients (28.4% vs. 19.8%; not significant), while infiltrates were slightly more frequently diagnosed among FLU patients (72.2% vs. 53.3%; not significant).

For 19 patients, a multiplex PCR on a nasopharyngeal swab was available (14 RSV patients, 5 FLU patients). Among the 14 patients with RSV infection for whom a multiplex PCR was available, adenovirus was concomitantly detected in two patients and coronavirus and *Bordetella pertussis* in one patient, each. In FLU patients, adenovirus and human metapneumovirus were detected in one patient, each. Blood cultures were ordered in 165 patients with RSV, of whom 9 were positive, all of which were deemed contaminants (5 coagulase negative staphylococci; 1 co-detection of *Staphylococcus epidermidis*, *Streptococcus mitis*, and *Streptococcus peroris*; 1 co-detection of *Micrococcus luteus* and *Pseudomonas stutzeri*; 1 *Micrococcus luteus*; 1 *Rothia dentocariosa*). For FLU patients, blood cultures were ordered in 54, with 3 positive cultures, all regarded as contamination (2 *Staphylococcus hominis*; 1 *Corynebacterium afermentans*).

Antibiotic utilization {#Sec11}
----------------------

Antibiotics were prescribed in 136/476 (28.6%) of RSV patients and 21/95 (22.1%) of FLU patients (*p* = 0.2107). A monotherapy was used in 77/136 (56.6%) in RSV patients and 15/21 (71.4%) of FLU patients (*p* = 0.2395), while the remaining fractions were prescribed a combination therapy. For RSV patients, the most frequently ordered therapies were aminopenicillin monotherapy in 44/136 (32.4%), ampicillin + flucloxacillin combination therapy in 41/136 (30.1%), and ampicillin + gentamicin combination therapy in 17/136 (12.5%). For FLU patients, ampicillin/sulbactam was prescribed in 7/21 (33.3%), followed by an aminopenicillin monotherapy in 4/21 (19.0%) and ampicillin + flucloxacillin combination therapy in 4/21 (19.0%). The distribution of prescribed antibiotics is depicted in Fig. [2](#Fig2){ref-type="fig"}. The median length of antibiotic therapy was 5.5 days for RSV patients (IQR 4--7) and 6 days for FLU patients (IQR 4--8) (*p* = 0.3680). Fig. 2Distribution of empiric antibiotics prescribed after hospitalization, absolute numbers; **a** RSV patients (*N* = 136); **b** influenza patients (*N* = 21); gen.: generation

Subgroup comparison -- RSV patients {#Sec12}
-----------------------------------

We compared RSV patients who received antibiotics (RSV+AB+) during the hospital stay to those without antibiotics (RSV+AB-). Children who were RSV+AB+ were significantly older than RSV+AB- (6 vs. 3 months; *p* = 0.0025) (Table [2](#Tab2){ref-type="table"}). Furthermore, they presented significantly more often with fever (91.2% vs. 60.6%; *p* \< 0.0001), a septic appearance (48.5% vs. 30%; *p* = 0.0002), pneumonia (76.8% vs. 39.1%; *p* \< 0.0001), acute otitis media (26.5% vs. 10%; *p* \< 0.0001), and a higher CRP on admission (26.9 mg/L vs. 4.3 mg/L; *p* \< 0.0001). During the hospital stay, RSV + AB+ children had significantly higher rates of chest radiographies (60.3% vs. 15.6%; *p* \< 0.0001), blood cultures obtained (52.2% vs. 27.6%; *p* \< 0.0001), oxygen therapy (80.1% vs. 60%; *p* \< 0.0001), intensive care stays (9.6% vs. 0.9%; *p* \< 0.0001), and longer hospital stays in total (6 days vs. 5 days; *p* \< 0.0001). Table 2Comparison of clincial and laboratory characteristics of RSV and FLU patients receiving antibiotics (AB+) to those not receiving antibiotics (AB-); median and interquartile range are indicated for continuous variablesVariablesRSV\
AB+RSV\
AB-*p*-valuesFLU\
AB+FLU\
AB-*p*-valuesN (%)136/476 (28.6%)340/476 (71.4%)21/95 (22.1%)74/95 (77.9%)Male76/136 (55.1%)193/340 (56.8%)ns11/21 (52.4%)44/74 (59.5%)nsAge, months6 (2--12)3 (2--7)0.002514 (9--18)11 (5--17.8)nsDuration of illness, days4 (2--5)3 (2--5)ns3 (2--5.3)2 (2--4)nsFever (≥38.0 °C)124/136 (91.2%)206/340 (60.6%)\< 0.000120/21 (95.2%)73/74 (98.6%)nsBody temperature on admission, °C38.0 (37.4--38.8)37.4 (37.0--38.1)\< 0.000138.2 (37.7--39-4)38.4 (37.4--39.3)nsPeak body temperature, °C39.2 (38.8--39.8)38.2 (37.5--39.2)\< 0.000140.0 (39.4--40.1)39.8 (39.1--40.0)nsOxygen saturation at admission, %96 (93--98)97 (95--98)0.001997 (93.3--98.3)98 (97--100)nsMinimal oxygen saturation, %89 (88--92)91 (88--95)\< 0.000190 (87.8--95.3)96 (95--98)nsNeed for intensive care13/136 (9.6%)3/340 (0.9%)\< 0.00011/21 (4.8%)0/74nsLength of stay, days6 (5--8.3)5 (3--7)\< 0.00016 (5--8.5)5 (3--7)0.0003Blood culture obtained71/136 (52.2%)94/340 (27.6%)\< 0.000112/21 (57.1%)42/74 (56.8%)nsCRP on admission, mg/L26.9 (9.7--51.2)4.3 (0--10.6)\< 0.000123.1 (5.9--58.4)4.9 (0--13.0)\< 0.0001Peak CRP, mg/L40.5 (19.2--61.5)7.9 (4.5--14.4)\< 0.000154.9 (11.7--76.8)9.4 (4.2--14.2)\< 0.0001WBC on admission, 10^9^/L11.6 (8.5--15.2)10.5 (8.5--12.7)ns9.9 (7.6--12.0)10.9 (7.1--13.7)nsChest radiography performed82/136 (60.3%)53/340 (15.6%)\< 0.000111/21 (52.4%)7/74 (9.5%)\< 0.0001Infiltrate on chest radiogram48/82 (58.5%)24/53 (45.3%)ns8/11 (72.7%)5/7 (71.4%)nsPreexisting antibiotic therapy19/136 (14.0%)13/340 (3.8%)0.00026/21 (13.7%)8/74 (3.9%)nsWell appearance1/136 (0.7%)31/340 (9.1%)0.00042/21 (9.5%)4/74 (5.4%)nsIll appearance60/136 (44.1%)185/340 (54.4%)0.053612/21 (57.1%)50/74 (67.6%)nsSeptic appearance66/136 (48.5%)102/340 (30%)0.00026/21 (28.6%)17/74 (23.0%)nsAcute otitis media36/136 (26.5%)34/340 (10%)\< 0.000112/21 (57.1%)21/74 (28.4%)0.0199Upper respiratory tract infection0/136 (0%)0/340 (0%)ns5/21 (23.8%)42/74 (56.8%)0.0123Bronchitis/Bronchiolitis31/136 (22.5%)207/340 (60.9%)\< 0.00011/21 (4.8%)5/74 (6.8%)nsPneumonia106/136 (76.8%)133/340 (39.1%)\< 0.000111/21 (52.4%)10/74 (13.5%)0.0005Fever of unknown origin0/136 (0%)0/340 (0%)ns4/21 (19.0%)17/74 (23.0%)nsOxygen therapy109/136 (80.1%)204/340 (60%)\< 0.000112/21 (57.1%)11/74 (14.9%)0.0002Length of oxygen therapy, days3 (2--6)2 (0--4)\< 0.00011 (0--6)00.0002

Subgroup comparison -- FLU patients {#Sec13}
-----------------------------------

For FLU patients, a significant difference upon clinical presentation was a higher rate of pneumonia (52.4% vs. 13.5%; *p* = 0.0005) and acute otitis media (57.1% vs. 28.4%; *p* = 0.0199) among children receiving antibiotics (FLU+AB+) compared to children without antibiotics (FLU+AB-) (Table [2](#Tab2){ref-type="table"}). Apart from that, FLU+AB+ children had significantly higher CRP on admission (23.1 mg/L vs. 4.9 mg/L; *p* \< 0.0001) and peak CRP (54.9 mg/L vs. 9.4 mg/L; *p* \< 0.0001) in the course of disease; a higher rate of chest radiography performed (52.4% vs. 9.5%; *p* \< 0.0001), higher need for oxygen therapy (57.1% vs. 14.9%; *p* = 0.0002), and a longer hospital stay (6 days vs. 5 days; *p* = 0.0003).

Risk factors for antibiotic use {#Sec14}
-------------------------------

We performed a multivariate logistic regression to identify risk factors associated with antibiotic utilization among both RSV and FLU. The best model fit for antibiotic use at any time point was achieved for the following factors (c-index 0.916) (Table [3](#Tab3){ref-type="table"}): otitis media (odds ratio 8.33; 95% confidence interval 3.58--19.37), peak CRP (OR 1.77; 95% CI 1.54--2.04), and the length of oxygen therapy (OR 1.40; 95% CI 1.13--1.74). Septic appearance (OR 4.882; 95% CI 0.866--27.505; *p* = 0.0723) was statistically not significant. Table 3Logistic regression model for antibiotic use at any time pointVariablesOdds ratio95% confidence interval*p*-valueOtitis media8.3253.577--19.374\< 0.0001Peak CRP1.7721.538--2.041\< 0.0001Length of oxygen therapy1.4041.130--1.7440.0022Septic appearance4.8820.866--27.5050.0723

The best model fit for antibiotic use on admission (c-index 0.896) (Table [4](#Tab4){ref-type="table"}) was achieved for otitis media (OR 4.5, 95% CI 2.1--9.4), CRP on admission (OR 1.7, 95% CI 1.5--2.0), and septic appearance (OR 8.95, 95% CI 1.5--54.1). Pneumonia as a potential risk factor (OR 3.629, 95% CI 0.902--14.602) missed statistical significance. Table 4Logistic regression model for antibiotic use on admissionVariableOdds ratio95% confidence interval*p*-valueOtitis media4.4962.141--9.439\< 0.0001CRP on admission1.6871.457--1.953\< 0.0001Septic appearance8.9501.481--54.0870.0169Pneumonia3.6290.902--14.6020.0696

Discussion {#Sec15}
==========

In this large retrospective four-season-analysis we present data on more than 570 children below the age of 2 years with RSV or FLU infection, demonstrating a high antibiotic use in a substantial proportion of children.

Recent systematic reviews with meta-analyses had shown that viral testing, including FLU and RSV, does not affect antibiotic prescription rates \[[@CR17], [@CR18]\], indicating that other factors pertaining to the decision-making of physicians need to be addressed by AMS measures.

Although RSV patients were significantly younger in our cohort, this apparently did not contribute to a higher rate of antibiotic utilization, as RSV children with antibiotics were significantly older than RSV children that did not receive antibiotics. Instead, driving factors for a potential antibiotic overuse were a high CRP, the presence of acute otitis media, septic appearance and the length of oxygen therapy.

FLU patients presented significantly more often with fever, febrile convulsions, acute otitis media, and upper respiratory tract infection or fever of unknown origin, while RSV patients presented significantly more often with a lower oxygen saturation, septic appearance, and lower respiratory tract infection or pneumonia.

We found higher rates of blood cultures obtained from FLU patients than from RSV patients, which in large part can be explained by the higher rate of febrile children in the FLU cohort, while chest radiographies were more frequently performed among those who received antibiotics within both groups. Interestingly, we found rates of chest infiltrates comparable between treated and non-treated patient groups. One possible explanation is that performing a chest radiograph serves as a surrogate for disease severity and hence influences the decision to prescribe antibiotics. In previous studies, it was hypothesized that less specific radiologic findings may have pushed physicians towards antibiotic treatment, even in the absence of infiltrates \[[@CR19]\]. Still, it is generally advised against routinely performing chest radiographs in children who present with typical clinical findings of viral bronchiolitis, of which the majority is caused by RSV \[[@CR20]\].

Male children were more predominant in both RSV and FLU cohorts, which had been reported similarly in previous studies \[[@CR21]\], yet without convincing explanations so far \[[@CR22]\]. Of note, the rate of antibiotic use before admission was 2.2 times higher among FLU patients, while during hospitalization, more RSV patients received antibiotics.

The antibiotic utilization in 28.6% of RSV and 22.1% of FLU patients respectively is lower than in comparable cohorts published in the recent past \[[@CR23], [@CR24]\], which may reflect a stronger reluctance to use antibiotics in children with point-of-care test confirmed viral infections at our hospital.

Complex medical comorbidities, such as chronic lung disease due to prematurity and congenital heart disease, are known risk factors for hospitalization due to RSV infection \[[@CR25], [@CR26]\]. In our cohort, we did not find any difference in these comorbidities between RSV and FLU patients.

The strengths of our study are the study size, allowing for robust statistical analyses, the long inclusion period, accounting for fluctuations of virus seasonality, and the consistency in standard of care during the inclusion period, thereby avoiding unwanted biasing effects.

Certain limitations of the study also merit critical appraisal. First, we obtained data retrospectively, bringing about the usual constraints and biases inherent to the nature of retrospective analyses. As such, we could not assess the effect of vaccination coverage, especially pertaining to influenza, on the study outcomes since these data were not systematically obtained. In Germany, currently no general recommendation for FLU vaccination for children exists, but only for those with chronic medical conditions. Secondly, no reference method was applied with regard to the correctness of antibiotic utilization. The correct judgement whether an antibiotic is warranted or not is hindered by the lack of a reference standard. Several methods exist to account for this, e.g. a panel of expert referees, blinded to each other, reviewing each case and adjudicating on the "correct" etiology, i.e. bacterial, viral, bacterial-viral co-infection, or unknown, as applied in other studies \[[@CR21], [@CR27]\]. Third, our cohort lacked an additional systematic viral testing beyond RSV and Influenza for all patients, making it impossible to judge whether other viruses, such as adenovirus, may have played a causative role, especially in cases with higher CRP \[[@CR28]\]. Other viruses, albeit rarer, such as the human metapneumovirus, can be equally or even more associated with antibiotic overuse in children, as described by Schreiner and colleagues \[[@CR29]\]. An extensive pathogen testing in conjunction with a control group of healthy children may have helped to better appraise the role of other viruses or bacteria, since some microorganisms can be found abundantly also in healthy controls \[[@CR11]\], and the co-presence of some pathogens have been reported to correlate with disease severity \[[@CR30]\]. Of note, O'Grady and colleagues had found that more than half of children with an acute respiratory infection had a viral-bacterial "co-detection" in nasal swabs, the bacterium in most cases being *Haemophilus influenzae* \[[@CR31]\]. In another study in children with lower respiratory tract infections \[[@CR32]\], the most common detected potentially pathogenic colonizers were *Haemophilus influenzae* (32.1%), *Moraxella catharralis* (26.7%), *Staphylococcus aureus* (17.7%) and *Streptococcus pneumoniae* (16.7%). Nevertheless, detection of bacterial colonizers may not help in the decision to initiate antibiotic therapy. Instead, there is evidence that the utilization of viral point-of-care diagnostics may prevent the usage of antibiotics \[[@CR33], [@CR34]\]. Overall, this fits well into the concept of diagnostic as well as antibiotic stewardship. Fourth, our cohort had a low case fatality rate, which reduces comparability to cohorts from other backgrounds, e.g. from low- and middle-income countries, where mortality may be higher \[[@CR35]\]. Finally, the low baseline rate of antibiotic utilization may limit the generalizability of our results to other settings where the culture of prescribing antibiotics especially in infants and young children below the age of 2 years may differ \[[@CR36]\] due to a lack of AMS or other reasons.

In light of the imperfection of both clinical features \[[@CR7]\] and laboratory parameters such as CRP \[[@CR37], [@CR38]\], novel diagnostics measures are needed to better distinguish between viral and bacterial infections and thereby help reducing unwarranted antibiotic therapy. New host-protein based assays, e.g. combining CRP with Myxovirus resistance protein A \[[@CR39]\], but also combinations of CRP and tumor-necrosis-factor related apoptosis inducing ligand and interferon-gamma induced protein 10, have shown very convincing results in studies \[[@CR21], [@CR40]--[@CR42]\], with high diagnostic accuracy and a potential to dampen unnecessary antibiotic use. Transcriptomic signatures have also shown to be very accurate in establishing the true etiology \[[@CR43], [@CR44]\], and although cost issues and turnaround times steadily improve \[[@CR45]\], practical feasibility and implementation into the clinical workflow are persisting challenges still to be taken.

Conclusions {#Sec16}
===========

In summary, we show that clinical appearance on admission, the presence of otitis media, but also a high CRP and the length of oxygen therapy are the main factors associated with antibiotic use in our cohort of in children below the age of 2 years with RSV or FLU infection. It remains to be proven in prospective studies if AMS interventions aiming at viral testing, e.g. as multiplex PCR, in conjunction with more precise biomarkers or combinations thereof can help to effectively reduce antibiotic treatment in children with RSV infection and Influenza.
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